newsfilter
← Latest News
GlobeNewswire·

Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

CMND
  • Clearmind Medicine Inc. (NASDAQ: CMND) submitted a formal response to the U.S. HHS Request for Information regarding MEAI as an intervention for addiction treatment.
  • The company proposes an innovative model using non-hallucinogenic neuroplastogens to provide scalable, inexpensive, & clinically effective treatment for Alcohol Use Disorder.
  • The submission highlights the proprietary candidate CMND-100, designed to promote neuroplasticity without hallucinogenic effects or the need for supervised dosing.
  • The document notes that approximately 10% of the U.S. population suffers from AUD, yet only 1 in 10 Americans receive treatment.
  • CMND-100 targets neural pathways like 5-HT1A to support moderation & long-term recovery with low abuse potential.
  • The initiative supports the Great American Recovery Initiative & President Trump's Executive Orders on addiction.
  • Clearmind aims to deliver safe therapies in community-based, rural, & underserved settings where access to care remains constrained.
  • The company holds an intellectual portfolio of nineteen patent families including 32 granted patents.